

TRANSFER OF VALUE DISCLOSURE SCHEME

UCB Transparency Report - Luxembourg 2025

Art. 36 ter. 3

Publication date: June 2026

Full name <small>Art. 36 bis</small>	HCP Municipality and postal code of the main practice / HCO Municipality and postal code of the main registered office <small>Art 36. quater</small>	Country of the main practice <small>Art. 36 bis2</small>	Address (street / number / box) of the main practice <small>Art. 36 quater</small>	Unique identification number OPTIONAL <small>Art. 36 quater</small>	Donations and grants <small>Art. 36 quater 2Ia</small>	Contributions to costs related to scientific events <small>(Art. 36 quater 2Ib & 36 quater 2 II a)</small>			Fees for services and consultancy <small>(Art. quater 2 I c & 36 quater 2 II b)</small>		TOTAL OPTIONAL
						Sponsorship agreements with HCOs / third parties appointed by HCOs to manage a scientific event	Registration fees	Travel and accommodation expenses	Fees	Related expenses included in the remuneration or agreed in the consultancy agreement, including travel and accommodation expenses related to the agreement	

PSS	INDIVIDUAL NAMED DISCLOSURE – (one line per HCP; all transfers of value made during the year to a given HCP will be aggregated – a detailed disclosure should only be made available to the concerned beneficiary or to the competent authorities upon request)											
						NA	NA	0.00 EUR	0.00 EUR	0.00 EUR	0.00 EUR	
	OTHERS NOT INCLUDED ABOVE if the information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount of transfers of value to these beneficiaries (Art. 36 quater 3)					NA	NA	879.00 EUR	2,044.80 EUR	0.00 EUR	0.00 EUR	2,923.80 EUR
	Number of beneficiaries (named list if indicated) (Art. 36 quater §3)					NA	NA	1	2	0	0	
% of the number of beneficiaries included in the aggregated disclosure out of the total number of beneficiaries disclosed (Art. 36 quater 3)					NA	NA	100%	100%	0	0	NA	

HCO	INDIVIDUAL NAMED DISCLOSURE – (one line per HCO (all transfers of value made during the year to a given HCO will be aggregated – a detailed disclosure should only be made available to the concerned beneficiary or to the competent authorities upon request))											
	SLN	Esch-Sur-Alzette	LU	Rue De L Alzette 23-25		0.00 EUR	2,500.00 EUR	0.00 EUR	0.00 EUR	0.00 EUR	0.00 EUR	2,500.00 EUR
	OTHERS NOT INCLUDED ABOVE if the information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount of transfers of value to these beneficiaries (Art. 44quater3)					0.00 EUR	0.00 EUR	0.00 EUR	0.00 EUR	0.00 EUR	0.00 EUR	
	Number of beneficiaries (named list if indicated) (Art. 44 quater3)					0	0	0	0	0	0	
% of beneficiaries included in the aggregated disclosure out of the total number of beneficiaries disclosed (Art. 44quater3)					0	0	0	0	0	0	NA	

R&D	AGGREGATED DISCLOSURE										
	Transfers of value related to research and development as defined in Art. 36 quater §5										TOTAL AMOUNT

PO	INDIVIDUAL NAMED DISCLOSURE – (one line per PO (all transfers of value made during the year to a given PO will be aggregated – a detailed disclosure should only be made available to the concerned beneficiary or to the competent authorities upon request))											
	Alzheimer Europe					0.00 EUR	10,000.00 EUR	0.00 EUR	0.00 EUR	6,720.00 EUR	0.00 EUR	16,720.00 EUR
	OTHERS NOT INCLUDED ABOVE if the information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount of transfers of value to these beneficiaries – Art. 36 quater §3					0.00 EUR	0.00 EUR	0.00 EUR	0.00 EUR	0.00 EUR	0.00 EUR	
	Number of beneficiaries (named list if indicated) – Art. 36 quater §3					0	0	0	0	0	0	
% of beneficiaries included in the aggregated disclosure out of the total number of beneficiaries disclosed – Art. 36 quater §3					0	0	0	0	0	0	NA	